Annals of Oncology· @Annals_Oncology · X·· 1 天前评分70
正文 · 原文
📢 #ESMO26 concomitant paper: OS from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs pbo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy.
🔗https://tinyurl.com/mt82dufd
@KalinskyKevin @BianchiniGP
197 浏览 · 2 赞 · 3 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.org来源：Annals of Oncology · x.com